Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

181. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). 27799159 2016 11 01 2017 03 11 1468-2060 76 4 2016 Apr Annals of the rheumatic diseases Ann. Rheum. Dis. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). 694-700 10.1136/annrheumdis-2016-209821 (...) To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs). In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy

EvidenceUpdates2016

182. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis 27900570 2018 11 13 2198-6576 4 1 2017 Jun Rheumatology and therapy Rheumatol Ther Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. 133-149 10.1007/s40744-016-0049-8 Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment (...) Rheumatoid arthritis Statins Tocilizumab 2016 09 15 2016 12 3 6 0 2016 12 3 6 1 2016 12 1 6 0 ppublish 27900570 10.1007/s40744-016-0049-8 10.1007/s40744-016-0049-8 PMC5443718

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

183. Medical expert testimony as conflict of interest regarding the onset of rheumatoid arthritis following trauma

Medical expert testimony as conflict of interest regarding the onset of rheumatoid arthritis following trauma 27920585 2018 11 13 1179-156X 8 2016 Open access rheumatology : research and reviews Open Access Rheumatol Medical expert testimony as conflict of interest regarding the onset of rheumatoid arthritis following trauma. 119-121 Sherry David D DD Division of Rheumatology, Department of Pediatrics, The Children's Hospital of Philadelphia Perelman School of Medicine at the University (...) of Pennsylvania, Philadelphia, PA, USA. eng Journal Article Comment 2016 11 23 New Zealand Open Access Rheumatol 101688698 1179-156X Open Access Rheumatol. 2016 Aug 17;8:77-80 27843373 JAMA. 2009 Nov 25;302(20):2230-4 19934424 J Law Med Ethics. 2012 Fall;40(3):482-7 23061575 Open Access Rheumatol. 2016 Aug 17;8:77-80 27843373 The author supplies medical expert opinion and testimony in cases involving juvenile idiopathic arthritis and trauma. The author reports no other conflicts of interest

Open access rheumatology : research and reviews2016 Full Text: Link to full Text with Trip Pro

184. Depression and anxiety after 2 years of follow-up in patients diagnosed with diabetes or rheumatoid arthritis

Depression and anxiety after 2 years of follow-up in patients diagnosed with diabetes or rheumatoid arthritis 28070410 2018 11 13 2055-1029 3 2 2016 Jul Health psychology open Health Psychol Open Depression and anxiety after 2 years of follow-up in patients diagnosed with diabetes or rheumatoid arthritis. 2055102916678107 10.1177/2055102916678107 We studied emotional health in patients with diabetes mellitus ( n = 89) or rheumatoid arthritis ( n = 100) aged 18-65 years, at the time of diagnosis (...) and after 24 months. Predictors for depression or anxiety according to the Hospital Anxiety and Depression scale after 2 years were assessed by logistic regression, with psychosocial factors and coping as dependent factors. There were many similarities between patients with diabetes mellitus or rheumatoid arthritis. Having children at home, low score on the Sense of Coherence scale, and high score on the coping strategy "protest" were important risk factors for depression and anxiety after 2 years

Health psychology open2016 Full Text: Link to full Text with Trip Pro

185. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF (...) inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitor at week 12. METHODS: In this 104-week, randomised, single-blind (double-blind until week 12 and investigator blind thereafter), parallel-group, head-to-head superiority study (EXXELERATE), eligible patients from 151 centres worldwide were aged 18 years or older with a diagnosis of rheumatoid arthritis at screening, as defined

Lancet2016

186. Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe 27817152 2018 11 13 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. 245-256 Benepali ® was the first etanercept (Enbrel ® ) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available (...) as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients' perceptions were similar to those of the nurses, this survey evaluated patients' perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries. Patients

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

188. Toward Electronic Health Recording: Evaluation of Electronic Patient-reported Outcome Measures System for Remote Monitoring of Early Rheumatoid Arthritis

Toward Electronic Health Recording: Evaluation of Electronic Patient-reported Outcome Measures System for Remote Monitoring of Early Rheumatoid Arthritis 27633823 2016 09 16 2016 12 02 0315-162X 43 12 2016 Dec The Journal of rheumatology J. Rheumatol. Toward Electronic Health Recording: Evaluation of Electronic Patient-reported Outcome Measures System for Remote Monitoring of Early Rheumatoid Arthritis. 2106-2112 To assess the use of electronic patient-reported outcome measures (ePROM (...) ) in standard clinical practice for early rheumatoid arthritis (RA) management, the ePROM ability to enhance clinical care, and how computing technology can improve the patients' adherence to therapy. In a double-blinded randomized-controlled study, 211 patients with early RA diagnosed according to American College of Rheumatology/European League Against Rheumatism criteria completed a PROM in paper format at their first clinic visit. Patients were then randomized to Group 1, which completed an ePROM

EvidenceUpdates2016

189. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 27697765 2016 10 04 2016 12 12 1468-2060 76 1 2017 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. 17-28 10.1136/annrheumdis-2016-209775 Patients (...) with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates

EvidenceUpdates2016

190. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial 27581208 2016 09 01 2016 12 09 1462-0332 55 12 2016 Dec Rheumatology (Oxford, England) Rheumatology (Oxford) Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial (...) , Admiraal de Ruyter Hospital, Goes. Grillet Bernard A BA Department of Rheumatology, Zorgsaam Hospital, Terneuzen, the Netherlands. Luime Jolanda J JJ Department of Rheumatology, Erasmus Medical Center. Weel Angelique E A M AE Department of Rheumatology, Erasmus Medical Center. Department of Rheumatology, Maasstad Hospital. eng Journal Article 2016 08 30 England Rheumatology (Oxford) 100883501 1462-0324 QALY cost–utility direct and indirect costs early arthritis rheumatoid arthritis worker productivity

EvidenceUpdates2016

191. Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial.

Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial. 27757177 2016 10 19 2017 02 24 8 8 2016 Aug Electronic physician Electron Physician Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial. 2700-2706 Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder with unknown etiology. Atorvastatin is a lipid-lowering agent that affects (...) . 2009;49(9):21-6 19772499 Diabetes Care. 2002 Jul;25(7):1198-202 12087019 Circulation. 2003 Sep 30;108(13):1560-6 12975259 J Rheumatol. 2007 Jul;34(7):1459-64 17552046 Am Heart J. 2005 Mar;149(3):451-7 15864233 Eur J Pharmacol. 2005 Jun 15;516(3):282-9 15970284 J Clin Endocrinol Metab. 2002 Feb;87(2):563-8 11836286 Scand J Rheumatol. 2009;38(4):235-9 19247848 Kardiologiia. 2007;47(2):25-30 17495819 Anti-inflammatory Atorvastatin Rheumatoid arthritis There is no conflict of interest to be declared. 2015

Electronic physician2016 Full Text: Link to full Text with Trip Pro

192. Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis.

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. 27747583 2016 10 17 2017 04 10 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. 257-270 Adalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation (...) . The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle, versus the current 40 mg/0.8 mL formulation in patients with rheumatoid arthritis (RA). Two identically designed, phase 2, randomized, single-blind, two-period crossover studies were conducted in Belgium and the Czech Republic (Study 1) and Australia, Canada

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

193. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis 27550304 2016 08 23 2017 02 20 1462-0332 55 11 2016 Nov Rheumatology (Oxford, England) Rheumatology (Oxford) The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society (...) for Rheumatology Biologics Register-Rheumatoid Arthritis. 2033-2039 To explore the influence of TNF inhibitor (TNFi) therapy and rituximab (RTX) upon the incidence of cancer in patients with RA and prior malignancy. The study population comprised RA subjects with a prior malignancy reported to the UK national cancer registers, recruited to the British Society for Rheumatology Biologics Register from 2001 to 2013. We compared rates of first incident malignancy in a TNFi cohort, RTX cohort and synthetic DMARDs

EvidenceUpdates2016

194. Tocilizumab (RoActemra) - Treatment of severe, active and progressive rheumatoid arthritis

Tocilizumab (RoActemra) - Treatment of severe, active and progressive rheumatoid arthritis Published 10 October 2016 Statement of Advice: tocilizumab (RoActemra ® ) 162mg Solution for Injection in Pre-Filled Syringe (No: 1201/16) Roche Products Ltd 09 September 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation Tocilizumab (RoActemra ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of severe, active and progressive (...) rheumatoid arthritis in adults not previously treated with methotrexate. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication / setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics

Scottish Medicines Consortium2016

195. Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis

Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis - GOV.UK GOV.UK uses cookies to make the site simpler. Search Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis From: Published: 17 October 2016 Therapeutic area: and Prescribing information has been updated to introduce a lower recommended (...) dose of 60 mg daily for patients with rheumatoid arthritis or ankylosing spondylitis. Contents Advice for healthcare professionals: the cardiovascular and other important risks of etoricoxib (Arcoxia) may increase with dose and duration of exposure. Therefore, the lowest effective daily dose should be used, and the need for treatment should be regularly reassessed the recommended dose is 60 mg once daily in patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may

MHRA Drug Safety Update2016

196. [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis]

[A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis] [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis] [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis] Yun JE, Park SH, Kim YJ, Lee LR, Kim JM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Yun JE, Park SH, Kim YJ, Lee LR, Kim JM. [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C -15-007. 2016 Authors' conclusions This study aims to assess the effectiveness of patient education interventions on health status in patients with rheumatoid arthritis and to evaluate the needs for patient education in Korea

Health Technology Assessment (HTA) Database.2016

197. Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe 27747586 2017 08 16 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali ® ) Versus Etanercept

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

198. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study 27747585 2018 11 13 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. 291-304 To assess the long-term safety and efficacy of subcutaneous tocilizumab (TCZ-SC) in US patients (...) with rheumatoid arthritis (RA) who rolled over from the two global phase 3 studies, SUMMACTA (NCT01194414) and BREVACTA (NCT1232569), into this open-label, single-arm, phase 3b study. Patients continued to receive TCZ-SC 162 mg weekly or every other week or switched from intravenous TCZ to TCZ-SC 162 mg qw for up to 84 weeks. The primary endpoint was the proportion of patients with serious adverse events (SAEs). Secondary endpoints included clinical efficacy, laboratory abnormalities, and immunogenicity

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

199. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.

Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. Importance: One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing the next treatment exists. Objective: To compare the efficacy of a non-TNF-targeted biologic (non-TNF) vs a second anti-TNF drug for patients with insufficient (...) response to a TNF inhibitor. Design, Setting, and Participants: A total of 300 patients (conducted between 2009-2012) with rheumatoid arthritis, with persistent disease activity (disease activity score in 28 joints-erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 [range, 0-9.3]) and an insufficient response to anti-TNF therapy were included in a 52-week multicenter, pragmatic, open-label randomized clinical trial. The final follow-up date was in August 2013. Interventions: Patients were randomly

JAMA2016

200. Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis

Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis 27921093 2018 11 13 2509-596X 2 4 2016 Nov Ultrasound international open Ultrasound Int Open Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis. E117-E123 Background: Arthrosonography has proven to be more sensitive and reliable (...) for the detection of synovitis than clinical examination, but a comprehensive examination of small joints is time-consuming. The automated breast volume scanner (ABVS) has been developed to allow automatic and reproducible series of consecutive B-mode pictures of the female breast. Objectives: To analyze the comparability of ABVS and conventional manual ultrasonography (mUS) for the detection of synovitis in hands and feet of patients with rheumatoid arthritis (RA). Methods: 45 patients with early

Ultrasound international open2016 Full Text: Link to full Text with Trip Pro